• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高效液相色谱法开发、验证及抗肿瘤 HSP90 抑制剂-PU-H71(NSC750424)的杂质特征分析。

HPLC method development, validation and impurity characterization for an antitumor Hsp90 inhibitor-PU-H71 (NSC 750424).

机构信息

SRI International, 333 Ravenswood Avenue, Menlo Park, CA 94025, USA.

SRI International, 333 Ravenswood Avenue, Menlo Park, CA 94025, USA.

出版信息

J Pharm Biomed Anal. 2014 Feb;89:34-41. doi: 10.1016/j.jpba.2013.10.021. Epub 2013 Oct 24.

DOI:10.1016/j.jpba.2013.10.021
PMID:24252723
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3954645/
Abstract

An HPLC method for the assay of the heat shock protein 90 inhibitor, PU-H71 (NSC 750424), has been developed and validated. The stress testing of PU-H71 was carried out in accordance with ICH guidelines Q1A (R2) under aqueous, acidic, alkaline, oxidative, thermolytic and photolytic conditions. The separation of PU-H71 from its impurities and degradation products was achieved within 50min on a Mac-Mod ACE 3 C18 column (150mm×4.6mm i.d., 3μm) with a gradient mobile phase comprising 20-95% acetonitrile in water, with 0.1% trifluroacetic acid in both phases. LC-quadrupole TOF/MS was used to obtain accurate mass data on various components as well as on their fragments for characterization of impurities and degradation products. The proposed HPLC assay method was validated for specificity, linearity (concentration range 0.1-0.3mg/mL, r≥0.9998), accuracy (recovery 99.7-101.1%), precision (intra-lab RSD≤1.39%, inter-lab RSD≤0.91%), sensitivity (LOD 0.08μg/mL), and ruggedness. The developed method was suitable for the assay and stability monitoring of PU-H71 drug substance.

摘要

已经开发和验证了一种用于测定热休克蛋白 90 抑制剂 PU-H71(NSC 750424)的 HPLC 方法。根据 ICH 指南 Q1A(R2),在水相、酸性、碱性、氧化、热解和光解条件下对 PU-H71 进行了强制降解试验。在 Mac-Mod ACE 3 C18 柱(150mm×4.6mm id,3μm)上,采用梯度流动相(两相中均含有 0.1%三氟乙酸的 20-95%乙腈),可在 50min 内实现 PU-H71 与其杂质和降解产物的分离。LC-四极杆飞行时间质谱(TOF/MS)用于获得各种成分的准确质量数据以及它们的碎片,以对杂质和降解产物进行表征。所提出的 HPLC 测定方法经过专属性、线性(浓度范围 0.1-0.3mg/mL,r≥0.9998)、准确度(回收率 99.7-101.1%)、精密度(内-实验室 RSD≤1.39%,外-实验室 RSD≤0.91%)、灵敏度(LOD 0.08μg/mL)和耐用性验证。所开发的方法适用于 PU-H71 原料药的测定和稳定性监测。

相似文献

1
HPLC method development, validation and impurity characterization for an antitumor Hsp90 inhibitor-PU-H71 (NSC 750424).高效液相色谱法开发、验证及抗肿瘤 HSP90 抑制剂-PU-H71(NSC750424)的杂质特征分析。
J Pharm Biomed Anal. 2014 Feb;89:34-41. doi: 10.1016/j.jpba.2013.10.021. Epub 2013 Oct 24.
2
HPLC method development, validation, and impurity characterization of a potent antitumor indenoisoquinoline, LMP776 (NSC 725776).高效液相色谱法用于一种强效抗肿瘤茚并异喹啉LMP776(NSC 725776)的方法开发、验证及杂质表征。
J Pharm Biomed Anal. 2016 May 30;124:267-273. doi: 10.1016/j.jpba.2016.02.036. Epub 2016 Feb 27.
3
HPLC method development, validation, and impurity characterization of a potent antitumor nucleoside, T-dCyd (NSC 764276).高效液相色谱法用于一种强效抗肿瘤核苷T-dCyd(NSC 764276)的方法开发、验证及杂质表征
J Pharm Biomed Anal. 2016 Nov 30;131:429-435. doi: 10.1016/j.jpba.2016.08.034. Epub 2016 Sep 9.
4
Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2.PU-H71对热休克蛋白90的抑制作用通过内质网应激和线粒体途径诱导癌细胞凋亡,并克服了Bcl-2所赋予的耐药性。
Biochim Biophys Acta. 2013 Jun;1833(6):1356-66. doi: 10.1016/j.bbamcr.2013.02.014. Epub 2013 Feb 26.
5
The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1.新型嘌呤骨架 HSP90 抑制剂 PU-H71 的抗骨髓瘤活性是通过抑制 HSP90A 和 HSP90B1 实现的。
J Hematol Oncol. 2010 Oct 26;3:40. doi: 10.1186/1756-8722-3-40.
6
Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma.新型 HSP90 抑制剂 PU-H71 单独及联合硼替佐米治疗尤文肉瘤的临床前疗效。
Mol Oncol. 2014 Mar;8(2):323-36. doi: 10.1016/j.molonc.2013.12.005. Epub 2013 Dec 15.
7
Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71.碘-124标记的热休克蛋白90抑制剂PU-H71的放射性合成
J Labelled Comp Radiopharm. 2016 Mar;59(3):129-32. doi: 10.1002/jlcr.3369. Epub 2016 Jan 25.
8
PU-H71, a novel Hsp90 inhibitor, as a potential cancer-specific sensitizer to carbon-ion beam therapy.新型热休克蛋白90(Hsp90)抑制剂PU-H71作为碳离子束治疗潜在的癌症特异性增敏剂。
J Radiat Res. 2016 Sep;57(5):572-575. doi: 10.1093/jrr/rrw054. Epub 2016 May 29.
9
The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non-homologous end joining.嘌呤骨架热休克蛋白90抑制剂PU-H71通过抑制同源重组和非同源末端连接的DNA修复,使癌细胞对重离子辐射敏感。
Radiother Oncol. 2016 Oct;121(1):162-168. doi: 10.1016/j.radonc.2016.08.029. Epub 2016 Sep 22.
10
Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.热休克蛋白90抑制剂PU-H71是一种恶性肿瘤的多模态抑制剂,在三阴性乳腺癌模型中可诱导完全缓解。
Proc Natl Acad Sci U S A. 2009 May 19;106(20):8368-73. doi: 10.1073/pnas.0903392106. Epub 2009 May 5.

引用本文的文献

1
A sensitive multidimensional method for the detection, characterization, and quantification of trace free drug species in antibody-drug conjugate samples using mass spectral detection.一种使用质谱检测技术对抗体-药物偶联物样品中的痕量游离药物种类进行检测、表征和定量的灵敏多维方法。
MAbs. 2016;8(2):306-17. doi: 10.1080/19420862.2015.1116659. Epub 2015 Dec 14.
2
The essential roles of chemistry in high-throughput screening triage.化学在高通量筛选分类中的重要作用。
Future Med Chem. 2014 Jul;6(11):1265-90. doi: 10.4155/fmc.14.60.

本文引用的文献

1
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.基于亲和性的蛋白质组学揭示了 HSP90 协调的癌症特异性网络。
Nat Chem Biol. 2011 Sep 25;7(11):818-26. doi: 10.1038/nchembio.670.
2
The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1.新型嘌呤骨架 HSP90 抑制剂 PU-H71 的抗骨髓瘤活性是通过抑制 HSP90A 和 HSP90B1 实现的。
J Hematol Oncol. 2010 Oct 26;3:40. doi: 10.1186/1756-8722-3-40.
3
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans.HSP90 是小鼠和人类依赖 JAK2 的骨髓增殖性肿瘤的治疗靶点。
J Clin Invest. 2010 Oct;120(10):3578-93. doi: 10.1172/JCI42442. Epub 2010 Sep 13.
4
A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.一种嘌呤骨架的热休克蛋白90抑制剂可使BCL-6不稳定,并在依赖BCL-6的B细胞淋巴瘤中具有特异性抗肿瘤活性。
Nat Med. 2009 Dec;15(12):1369-76. doi: 10.1038/nm.2059. Epub 2009 Nov 22.
5
Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.热休克蛋白90抑制剂PU-H71是一种恶性肿瘤的多模态抑制剂,在三阴性乳腺癌模型中可诱导完全缓解。
Proc Natl Acad Sci U S A. 2009 May 19;106(20):8368-73. doi: 10.1073/pnas.0903392106. Epub 2009 May 5.
6
New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.热休克蛋白90(Hsp90)抑制剂作为抗癌治疗药物的新进展:作用机制、临床前景及更多潜力
Drug Resist Updat. 2009 Feb-Apr;12(1-2):17-27. doi: 10.1016/j.drup.2008.12.002.
7
Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer.选择性化合物将Hsp90定义为小细胞肺癌中细胞凋亡的主要抑制剂。
Nat Chem Biol. 2007 Aug;3(8):498-507. doi: 10.1038/nchembio.2007.10. Epub 2007 Jul 1.
8
The middle domain of Hsp90 acts as a discriminator between different types of client proteins.热休克蛋白90(Hsp90)的中间结构域可区分不同类型的客户蛋白。
Mol Cell Biol. 2006 Nov;26(22):8385-95. doi: 10.1128/MCB.02188-05. Epub 2006 Sep 18.
9
Structure and mechanism of the Hsp90 molecular chaperone machinery.热休克蛋白90(Hsp90)分子伴侣机制的结构与作用机制。
Annu Rev Biochem. 2006;75:271-94. doi: 10.1146/annurev.biochem.75.103004.142738.
10
Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90.热休克蛋白90的高效水溶性嘌呤骨架抑制剂的鉴定
J Med Chem. 2006 Jan 12;49(1):381-90. doi: 10.1021/jm0508078.